Holen Sie sich die Stockscreener-App
2.27
10.55%
0.23
Handel nachbörslich:
2.15
-0.12
-5.29%
Schlusskurs vom Vortag:
$2.04
Offen:
$2.01
24-Stunden-Volumen:
1.70M
Relative Volume:
5.75
Marktkapitalisierung:
$60.59M
Einnahmen:
$48.20M
Nettoeinkommen (Verlust:
$-35.05M
KGV:
-1.4484
EPS:
-1.5673
Netto-Cashflow:
$-13.02M
1W Leistung:
+10.55%
1M Leistung:
-2.79%
6M Leistung:
+33.44%
1J Leistung:
-18.58%
1-Tages-Spanne:
$2.01
$2.35
1-Wochen-Bereich:
$1.9907
$2.35
52-Wochen-Spanne:
$1.06
$5.22
Celularity Inc Stock (CELU) Company Profile
Firmenname
Celularity Inc
Sektor
Branche
Telefon
(908) 768-2170
Adresse
170 PARK AVE, FLORHAM PARK
Vergleichen Sie CELU mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
2.27 | 54.45M | 48.20M | -35.05M | -13.02M | -1.5673 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-01-30 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2022-12-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-06-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-04-06 | Herabstufung | Truist | Buy → Hold |
| 2022-01-28 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-24 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Celularity Inc Aktie (CELU) Neueste Nachrichten
Celularity’s diabetic foot ulcer therapy shows promise in clinical trial By Investing.com - Investing.com Australia
Celularity Inc. Announces Positive Phase 2 Results for PDA-002 in Treating Diabetic Foot Ulcers Complicated by Peripheral Artery Disease - Quiver Quantitative
Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease - Stock Titan
Evaluating Celularity Inc. with trendline analysisWeekly Trade Review & High Conviction Buy Zone Alerts - newser.com
Is Celularity Inc. stock cheap at current valuationJuly 2025 Closing Moves & Weekly High Return Forecasts - newser.com
Is Celularity Inc. Equity Warrant stock supported by strong cash flowsSell Signal & Smart Allocation Stock Tips - newser.com
How to track smart money flows in Celularity Inc. Equity Warrant2025 Big Picture & Verified Entry Point Signals - newser.com
Celularity Inc. Equity Warrant recovery potential after sell off2025 Earnings Surprises & Community Consensus Trade Alerts - newser.com
Applying big data sentiment scoring on Celularity Inc. Equity WarrantEarnings Risk Report & High Return Stock Watch Alerts - newser.com
Candlestick signals on Celularity Inc. stock todayJuly 2025 Earnings & Expert Verified Movement Alerts - newser.com
Published on: 2025-10-14 00:55:53 - newser.com
Multi asset correlation models including Celularity Inc. Equity WarrantWeekly Profit Recap & Weekly Breakout Watchlists - newser.com
What momentum shifts mean for Celularity Inc. Equity WarrantMarket Growth Review & Free Fast Gain Swing Trade Alerts - newser.com
Analyzing Celularity Inc. with multi timeframe charts2025 Market Sentiment & Weekly High Return Opportunities - newser.com
How sentiment analysis helps forecast Celularity Inc.Analyst Upgrade & Smart Allocation Stock Tips - newser.com
Can Celularity Inc. Equity Warrant stock sustain market leadershipAnalyst Upgrade & Verified Entry Point Signals - newser.com
Celularity Inc. Equity Warrant stock trendline breakdownJuly 2025 PostEarnings & Free Real-Time Volume Trigger Notifications - newser.com
Celularity Inc. Equity Warrant stock outlook for YEARTreasury Yields & Daily Chart Pattern Signal Reports - newser.com
Is Celularity Inc. forming a bottoming baseTrade Entry Report & Real-Time Stock Movement Alerts - newser.com
Can Celularity Inc. stock hit analyst price targetsJuly 2025 PreEarnings & Real-Time Price Movement Reports - newser.com
Published on: 2025-10-13 02:37:08 - newser.com
How to recover losses in Celularity Inc. Equity Warrant stockQuarterly Portfolio Report & Smart Investment Allocation Insights - newser.com
Using Python tools to backtest Celularity Inc. Equity Warrant strategies2025 Earnings Impact & AI Enhanced Trading Signals - newser.com
Is Celularity Inc. Equity Warrant stock cheap at current valuationJuly 2025 Recap & Safe Capital Growth Stock Tips - newser.com
Risk adjusted return profile for Celularity Inc. Equity Warrant analyzedMarket Weekly Review & Daily Risk Controlled Trade Plans - newser.com
Will Celularity Inc. Equity Warrant stock go up soonJuly 2025 Sentiment & Accurate Buy Signal Notifications - newser.com
How to monitor Celularity Inc. Equity Warrant with trend dashboards2025 Momentum Check & Community Supported Trade Ideas - newser.com
Weiss Ratings Reiterates "Sell (D-)" Rating for Celularity (NASDAQ:CELU) - MarketBeat
Celularity Inc Stock Analysis and ForecastMarket Sentiment Surveys & Get Alerts Before Market Turns Ugly - earlytimes.in
Celularity Inc Equity Warrant Stock Analysis and ForecastRisk Mitigation Techniques & Low Risk Trading Plans - earlytimes.in
Market reaction to Celularity Inc. Equity Warrant’s recent newsWeekly Gains Summary & Stepwise Trade Signal Implementation - newser.com
Will Celularity Inc. stock benefit from green energy trends2025 Valuation Update & Daily Chart Pattern Signals - newser.com
Can Celularity Inc. Equity Warrant recover in the next quarterWeekly Trade Report & Long-Term Growth Stock Strategies - newser.com
What MACD signals say about Celularity Inc.2025 Retail Activity & Free Weekly Chart Analysis and Trade Guides - newser.com
Will a bounce in Celularity Inc. Equity Warrant offer an exitEarnings Risk Summary & Advanced Technical Analysis Signals - newser.com
Celularity Stock Price, Quotes and Forecasts - Benzinga
Detecting price anomalies in Celularity Inc. Equity Warrant with AI2025 Risk Factors & AI Based Buy and Sell Signals - newser.com
Live market analysis of Celularity Inc.Weekly Trade Recap & Free Community Consensus Stock Picks - newser.com
Finanzdaten der Celularity Inc-Aktie (CELU)
Umsatz
Nettogewinn
Free Cashflow
ENV
Celularity Inc-Aktie (CELU) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hariri Robert J | Chief Executive Officer |
Apr 13 '25 |
Option Exercise |
0.00 |
3,281 |
0 |
21,482 |
| Haines John R | Senior Exec Vice President |
Apr 13 '25 |
Option Exercise |
0.00 |
1,641 |
0 |
29,698 |
| Beers David C | Chief Financial Officer |
Apr 13 '25 |
Option Exercise |
0.00 |
1,025 |
0 |
18,561 |
| Brigido Stephen | Pres., Functional Regeneration |
Feb 17 '25 |
Option Exercise |
0.00 |
10,000 |
0 |
11,641 |
| Beers David C | Chief Financial Officer |
Feb 17 '25 |
Option Exercise |
0.00 |
12,500 |
0 |
21,932 |
| Haines John R | Senior Exec Vice President |
Feb 17 '25 |
Option Exercise |
0.00 |
20,000 |
0 |
35,092 |
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):